MyHealthChecked PLC Statement re. online comment (7889Y)
May 09 2023 - 3:36AM
UK Regulatory
TIDMMHC
RNS Number : 7889Y
MyHealthChecked PLC
09 May 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
MyHealthChecked PLC
( " MyHealthChecked " or the "Company " )
Statement re. online comment
MyHealthChecked PLC (AIM: MHC), the consumer home-testing
healthcare company, notes online comment regarding the
MyHealthChecked portfolio of at-home wellness tests now being
available via a major UK retail partner.
As reported in the recent preliminary results on 3 April 2023,
MHC is actively developing B2B2C customer relationships in
preparation to launch an expanded portfolio of at-home wellness
tests nationwide in 2023.
The Company is aware that MyHealthChecked products have been
added temporarily and in draft to a retail partner's website,
however no formal agreement has been signed and the Company remains
at an advanced stage of negotiations. Further updates will be made
to shareholders in due course.
For further information contact:
MyHealthChecked PLC www.myhealthchecked.com
Penny McCormick, Chief Executive via Walbrook PR
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Dowgate Capital Limited (Broker) Tel: +44 (0)20 3903 7715
David Poutney / Nicholas Chambers
Walbrook PR Ltd (Media Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
& IR)
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44
(0)7407 804 654
About MyHealthChecked PLC (
https://investors.myhealthchecked.com/ )
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted
pioneering UK healthcare company focused on a range of at-home
healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home
rapid tests, as well as DNA, RNA and blood sample collection kits
which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, whilst the sample
collection kits enable the collection of blood, urine, nasal or
mouth swab samples that are analysed in partner laboratories for a
range of biomarkers. The tests will also be made available online
and will be viable for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a
change in mindset as customers become more familiar with the
concept of accessible healthcare in the growing at home testing kit
market with a focus on accessibility at the right price, led by
UK-based experts.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
STRUPUWWAUPWUMB
(END) Dow Jones Newswires
May 09, 2023 03:36 ET (07:36 GMT)
MyHealthChecked (AQSE:MHC.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
MyHealthChecked (AQSE:MHC.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024